Crossmark

Proteolytic single hinge cleavage of pertuzumab impairs its Fc effector function and antitumor activity in vitro and in vivo

Crossref DOI link: https://doi.org/10.1186/s13058-018-0972-4

Published Online: 2018-06-01

Published Print: 2018-12

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Hsiao, Hao-Ching

Fan, Xuejun

Jordan, Robert E.

Zhang, Ningyan

An, Zhiqiang http://orcid.org/0000-0001-9309-2335
Funding

Funding for this research was provided by:

CPRIT (RP150230, PR150551)

Welch Foundation (AU-0042-20030616)
License Information

Text and Data Mining valid from 2018-06-01
More Information

Article History

Received: 22 November 2017

Accepted: 26 April 2018

First Online: 1 June 2018

Ethics approval

: All animal procedures and care were conducted in accordance with the animal care and use guidelines and the protocol was approved by the Animal Welfare Committee (AWC) of the University of Texas Medical School at Houston. No additional ethical approvals or consents were required.

: All authors approved of the manuscript and consented to its publication.

: The authors declare that they have no competing interests.

: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.